Mirae Asset Global Investments Co. Ltd. Buys 4,645 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 26.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 22,156 shares of the medical equipment provider’s stock after purchasing an additional 4,645 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Zimmer Biomet were worth $2,361,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of ZBH. GAMMA Investing LLC raised its stake in shares of Zimmer Biomet by 39.0% in the third quarter. GAMMA Investing LLC now owns 1,371 shares of the medical equipment provider’s stock valued at $148,000 after acquiring an additional 385 shares during the period. Brookstone Capital Management raised its position in Zimmer Biomet by 5.3% in the 3rd quarter. Brookstone Capital Management now owns 6,388 shares of the medical equipment provider’s stock worth $690,000 after purchasing an additional 322 shares during the period. CWM LLC lifted its stake in Zimmer Biomet by 7.4% in the third quarter. CWM LLC now owns 6,966 shares of the medical equipment provider’s stock worth $752,000 after purchasing an additional 481 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt grew its stake in shares of Zimmer Biomet by 575.8% during the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 2,230 shares of the medical equipment provider’s stock valued at $241,000 after buying an additional 1,900 shares during the last quarter. Finally, Exchange Traded Concepts LLC raised its holdings in shares of Zimmer Biomet by 3,043.1% in the third quarter. Exchange Traded Concepts LLC now owns 1,603 shares of the medical equipment provider’s stock worth $173,000 after buying an additional 1,552 shares during the period. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on ZBH. Royal Bank of Canada cut their price objective on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday. Wells Fargo & Company upped their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Stifel Nicolaus boosted their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. Raymond James reduced their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research report on Friday. Finally, Oppenheimer lowered their price target on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a report on Tuesday, October 15th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $124.70.

Zimmer Biomet Trading Down 1.6 %

NYSE ZBH opened at $101.01 on Monday. The firm has a market cap of $20.11 billion, a PE ratio of 22.70, a price-to-earnings-growth ratio of 1.83 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 52 week low of $99.93 and a 52 week high of $133.90. The company has a quick ratio of 0.70, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The company has a 50 day moving average price of $107.34 and a 200 day moving average price of $108.08.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter last year, the firm posted $2.20 earnings per share. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.25 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were paid a dividend of $0.24 per share. The ex-dividend date was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.95%. Zimmer Biomet’s payout ratio is 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.